載入...
Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
The treatment options for Fabry disease (FD) are enzyme replacement therapy (ERT) with agalsidase alfa or beta, and the oral pharmacological chaperone migalastat. Since few data are available on the effects of switching from ERT to migalastat, we performed a single-center observational study on seve...
Na minha lista:
| 發表在: | Eur J Hum Genet |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer International Publishing
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7784987/ https://ncbi.nlm.nih.gov/pubmed/32647377 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41431-020-0677-x |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|